CTOs on the Move

Viropro

www.viropro.com

 
Viropro is a Mont-Royal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.viropro.com
  • 8515 Place Devonshire
    Mont-Royal, QC CAN H4P 2K1
  • Phone: 514.731.8776

Executives

Name Title Contact Details

Similar Companies

International Stem Cell Corporation

International Stem Cell Corporation is a Oceanside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immuno Vaccine

Immuno Vaccine is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioServ Corporation

BioServ Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AcariaHealth

AcariaHealth is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tanner Pharma

For over 18 years, Tanner Pharma Group has provided highly specialized pharmaceutical services to its partners around the world. Leading pharmaceutical and biotech companies partner with Tanner Pharma to license and commercialize their products in challenging international markets, develop and manage their Global Access Programmes, and source comparator drugs for clinical trials and bioanalysis. By partnering with Tanner Pharma, manufacturers are able to focus on their primary markets and strategies while ensuring that the services they need will follow a strictly controlled protocol of quality. Headquartered in the U.S. with offices in London, São Paulo and Mexico City, Tanner Pharma Group`s reach includes Europe, Asia, the Middle East, Australia, Canada and Latin America. We measure our value as a company based on the lives we help to improve. For all of us involved in the pharmaceutical supply chain - manufacturers, distributors, pharmacists, doctors, and others - it is ultimately the patient that matters most. Therefore, we start each day with a renewed commitment to ethically supply unlicensed medicines to markets where access continues being a challenge.